-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170

Benzinga·08/10/2026 18:18:02
Listen to the news
Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $145 to $170.